{"id":"NCT02516410","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation and With a Second CFTR Mutation That Is Not Likely to Respond to VX-661 and/or Ivacaftor Therapy (F508del/NR)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08","primaryCompletion":"2016-06-07","completion":"2016-06-07","firstPosted":"2015-08-05","resultsPosted":"2018-06-12","lastUpdate":"2018-06-12"},"enrollment":168,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"VX-661 plus ivacaftor combination","otherNames":[]},{"type":"DRUG","name":"Ivacaftor","otherNames":["IVA","VX-770"]},{"type":"DRUG","name":"Placebo (matched to VX-661 plus ivacaftor combination)","otherNames":[]},{"type":"DRUG","name":"Placebo (matched to ivacaftor)","otherNames":[]}],"arms":[{"label":"VX-661/IVA","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Study to evaluate the efficacy of VX-661 in combination with ivacaftor (IVA, VX-770) through Week 12 in participants with cystic fibrosis (CF) who are heterozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene and with a second CFTR mutation that is not likely to respond to VX-661 and/or IVA therapy (F508del/not responsive \\[NR\\]).","primaryOutcome":{"measure":"Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 12","timeFrame":"Baseline, Through Week 12","effectByArm":[{"arm":"Placebo","deltaMin":-0.1,"sd":0.6},{"arm":"VX-661/IVA","deltaMin":1,"sd":0.6}],"pValues":[{"comp":"OG000 vs OG001","p":"= 0.1176"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":41,"countries":["United States","Australia","Austria","Canada","France","Israel","Spain"]},"refs":{"pmids":["32546431"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":85},"commonTop":["Cough","Infective pulmonary exacerbation of cystic fibrosis","Sputum increased","Nasal congestion","Haemoptysis"]}}